Systemic Therapeutics Corp. is a Canadian pre-clinical stage, biotechnology company specialized in the development of new therapies focusing on the master regulator of lipid metabolism, sterol regulatory-element binding proteins (SREBP), based on first-in-class small molecule SREBP inhibitors. The company aims to provide new treatment options for metabolic conditions such as dyslipidemia, via reduction of circulating PCSK9, and Non-Alcoholic Fatty Liver Disease. Systemic is pioneering a new approach to the care of metabolic disorders.
Co-Founder, Executive Chairman and Chief Scientific Officer
Co-Founder and Vice President, Drug Discovery
Co-Founder and Chief Medical Officer
Co-Founder and Vice President, Business Development
Intellectual Property
Fundraising
Are you developing and/or redesigning new green products, services, processes, and technologies that reduce environmental impact?
The i.d.e.a.™ Fund program focuses on supporting a more sustainable economy while fostering an inclusive and equitable growth in southern Ontario. Find out if you’re eligible to access up to $20,000 in matching seed funding and 30 hours of expert mentorship.
Applications are open from June 16 to July 7, 2025.
